By continuing to use this website, you agree to the use of cookies. You can find out more by following this link.

Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      •  

       

      Summary of Product Characteristics
      Important Safety Information
      Dosing Schedule Simulator

      SKYRIZI (risankizumab) is a selective IL-23/p19 inhibitor indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.


       

      Upcoming events

      melinda gooderham

      Expert Dermatologists reflect on SKYRIZI data

      On-demand webinar

      Prof van de Kerkhof and Prof Strober discuss the SKYRIZI Phase 3 Study IMMhance data.

       

      Register
      aad

      American Academy of Dermatology | Association

      March 20–24, 2020 | Denver, Colorado

      2020 Annual Meeting

       

      Learn More

      I want to receive more information via a product specialist

      Go


       

      SUMMARY OF PRODUCT CHARACTERISTICS


       

      This website belongs to internal AbbVie’s initiative and it reflects a possible experience our hcp could have in Abbvie Pro

      Copyright © 2019 AbbVie Inc. SKZD-190010 North Chicago, Illinois, U.S.A.

      Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

      Data of Preparation: September 2019

      Approval code [approvalCode]